Ask AI
ProCE Banner Activity

Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma

Podcast Episodes

Listen to this audio podcast with expert insights and overview of the latest data for immune checkpoint inhibitors for advanced or metastatic hepatocellular carcinoma (HCC), for intermediate HCC in combination with TACE, and the latest guidelines for high-risk early HCC. 

Released: July 22, 2025

Expiration: January 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Eisai and Merck Sharp & Dohme LLC.

Eisai

Merck Sharp & Dohme, LLC

Disclosure

Primary Author

Joseph W. Franses, MD, PhD: consultant/advisor/speaker: Eisai, Foundation Medicine, Genentech, Guardant Health; researcher: AbbVie, Alnylam, Genentech, Iterion Therapeutics, Omega Therapeutics.

Neehar Parikh, MD, MS: consultant/advisor/speaker: AstraZeneca, Exact Sciences, Exelixis, Fujifilm Medical, Genentech, Sirtex.

Mark Yarchoan, MD: grant (paid to institution): Bristol Myers Squibb, Genentech; consultant/advisor/speaker: AstraZeneca, Exelixis, Incyte, Lantheus; owner: Adventris.